HR+/HER2-mBC的药理管理:以临床为导向的审查
Elena Diana Chiru1, Lina Sojak2, Julia Landin1
1University Center for Hematology and Oncology, Cantonal Hospital Baselland, Liestal, Switzerland.
激素受体阳性乳腺癌的治疗方法正在发展. 新疗法针对内分泌抵抗和特定突变,改善转移性疾病的结果,并为个性化医疗铺平道路.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌 (BC) 是全球女性最常见的癌症.
- 激素受体阳性 (HR+),HER2阴性亚型占BC病例的75%左右.
- 内分泌疗法 (ET) 对HR+BC至关重要,但面临阻力,特别是在转移性环境中.
研究的目的:
- 审查HR+转移性乳腺癌 (mBC) 的当前和新兴治疗策略.
- 突出解决ET耐药性和改善生存结果的进展.
- 强调个性化医疗在HR+mBC管理中的作用.
主要方法:
- 审查最近的临床进展和治疗剂.
- 对新型药物类别的分析,包括CDK4/6抑制剂,SERD,PROTAC,PARPi和ADC.
- 针对特定突变 (ESR1,BRCA) 和通路 (AKT/PIK3CA) 的向治疗方法的讨论.
主要成果:
- CDK4/6抑制剂改变了HR+ HER2-mBC的第一线治疗方法.
- 新型药物显示对ET耐药性和特定突变的有效性.
- 像T-DXd这样的抗体-药物合物 (ADC) 在HER2-低/超低子组中延长生存期.
- 针对性疗法为具有特定途径改变的患者提供了改善的PFS.
结论:
- 新兴疗法和个性化方法对于克服HR+mBC中的ET抵抗至关重要.
- 治疗和组合策略的最佳顺序需要持续的临床研究.
- 治疗的进步为HR+mBC患者提供了更好的生存率和个性化的选择.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Heart Failure V: Medical Management
